Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
GEVA > SEC Filings for GEVA > Form 8-K on 24-Oct-2013All Recent SEC Filings

Show all filings for SYNAGEVA BIOPHARMA CORP



Entry into a Material Definitive Agreement, Creation of a Direct Financia

Item 1.01. Entry into a Material Definitive Agreement.

On October 22, 2013, Synageva BioPharma Corp. ("Synageva") and RP Gateway, LLC (the "Landlord") entered into a lease agreement (the "Lease") under which Synageva will lease from the Landlord approximately twelve acres of land located in Oconee County, Georgia, including two to-be-constructed buildings containing approximately 35,000 square feet each (the "Premises") for future additional manufacturing facilities.

Synageva will occupy the Premises in stages as construction is completed. Synageva currently anticipates that it will begin occupying a portion of the Premises in February 2014.

The initial term of the Lease is approximately 124-months from commencement date of the lease, which is currently expected in February 2014. The initial rent for the Premises beginning in the fifth month following the date on which the Landlord's construction of the buildings on the Premises will be $36,167 per month plus certain operating expenses and taxes. Synageva has an option to extend the Lease for two successive periods of five years.

Synageva has the right to terminate the Lease if the Landlord fails to satisfy certain conditions relating to the ownership and development of the Premises.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease is incorporated into this Item 2.03 by reference.

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Synageva and Alicia Secor have agreed that Ms. Secor will depart the Company. The Company and Ms. Secor have agreed on separation terms that include confidentiality, non-competition, severance and certain other benefits. The separation is effective as of October 23, 2013.

Item 8.01. Other Events.

Dr. Ulrich (Uli) Goldmann, will be joining Synageva on November 11, 2013 as Senior Vice President of Global Market Access and Medical Affairs. Dr. Goldmann's experience includes serving as Senior Vice President of Global Medical Operations at Genzyme, a Sanofi company, Vice President and Head of Global Medical Affairs at Novartis and as Group Vice President of the Global Pharmaceutical Business at Schering Plough.

  Add GEVA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GEVA - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.